177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases amenable to liver-directed therapy who have progressed on at least one prior androgen pathway inhibitor.

Trial Details

NCT ID
NCT07145177
Phase
PHASE1
Sponsor
University of California, San Francisco
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 177Lu-PSMA-617
  • Ablation
  • Trans-arterial chemoembolization (TACE)
  • Positron Emission Tomography (PET)/Computerized tomography (CT)
  • Tumor Biopsy
  • Questionnaire
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Histologically confirmed prostate cancer.
  • Progressive disease by PCWG3 criteria at study entry.
  • Male participants who are at least 18 years of age on the day of signing informed consent.
  • Castrate level of serum testosterone at study entry (\< 50 ng/dL). Note: Participants without prior bilateral orchiectomy are required to remain on…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →